2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.68 (Poster)Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy

PP01.68 (Poster)Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy

Back to course

Pdf Summary

This summary is about a real-world study that investigated the characteristics and treatment patterns of patients with non-small cell lung cancer (NSCLC) who had a specific genetic mutation called EGFR exon 20 insertion (ex20ins). The study focused on two treatments, amivantamab (AMI) and mobocertinib (MOBO), and examined their effectiveness and tolerability after platinum-based chemotherapy.<br /><br />The study analyzed data from electronic health records and included patients who started either AMI or MOBO monotherapy after chemotherapy. The baseline characteristics of the patients were collected, including age, gender, race, smoking status, and comorbidity index. The study evaluated two real-world indicators of treatment success, which were time to next treatment (TTNT) and time to treatment discontinuation (TTD).<br /><br />The results showed that the cumulative probability of TTNT decreased over time for both AMI and MOBO treatments. The median TTNT for AMI was approximately 9 months, while for MOBO it was 6 months. These findings suggest that patients treated with AMI had similar outcomes to those observed in clinical trials, while patients treated with MOBO had a shorter TTNT compared to its trial data, indicating potential differences in its effectiveness and tolerability in real-world settings.<br /><br />The study acknowledged some limitations, such as the descriptive nature of the analyses and reliance on potentially incomplete or inaccurate clinical data. Furthermore, the study population may not be fully representative of all patients with EGFR ex20ins mutations, limiting the generalizability of the findings.<br /><br />Overall, this study provides valuable insights into the real-world treatment patterns and outcomes of patients with EGFR ex20ins mutation treated with AMI or MOBO. The findings underscore the importance of monitoring TTNT and TTD as indicators of treatment success in NSCLC and suggest potential differences in the real-world performance of MOBO compared to clinical trials. Further research and follow-up are needed to fully understand the effectiveness and safety of these treatments in real-world settings.

Asset Subtitle

Alexander Spira

Keywords

non-small cell lung cancer

EGFR exon 20 insertion

amivantamab

mobocertinib

platinum-based chemotherapy

time to next treatment

time to treatment discontinuation

real-world study

treatment patterns

effectiveness